Comparison of sentinel lymph node mapping with comprehensive lymphadenectomy in p53-mutated endometrial cancer: a prospective, multi-center, non-inferiority, open-label, de-escalation, randomized, controlled trial (Study Protocol - SENTIMETREP53).

Fiche publication

Date publication

février 2026

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric , Pr RAMANAH Rajeev , Dr EBERST Lauriane , Pr AKLADIOS Chérif , Dr HOTTON Judicaël

Tous les auteurs :
Akladios C, Lecointre L, Lefebvre F, Eberst L, Menoux I, Ouldamer L, Lavoue V, Huchon C, Dabi Y, Gertych W, Guyon F, Laas E, Bonneau C, Kerbage Y, Chauleur C, Fauvet R, Brun JL, Raimond E, Gauthier T, Costaz H, Rouzier R, Hotton J, Marchal F, Loaec C, Ramanah R, Chopin N, Querleu D, Jochum F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41796475

Résumé

The therapeutic value of lymphadenectomy in endometrial cancer remains controversial, particularly in high-risk patients as defined by the European Society of Gynaecological Oncology-European Society for Radiotherapy and Oncology 2021 histologic and molecular classification. While pelvic and para-aortic lymphadenectomy is the standard of care for high-risk endometrial cancer, sentinel lymph node (SLN) mapping has emerged as a promising alternative for low-risk patients with reduced post-operative morbidity. Recently, the advent of molecular classification has significantly influenced the diagnosis and management of endometrial cancer. In particular, p53 mutation has been recognized as an important prognostic marker and has been included in the criteria for high-risk classification.